What makes someone stop a lung fibrosis drug? a study asks patients directly
NCT ID NCT07722507
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The findings may help improve shared decision-making between patients and doctors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- antifibrotic therapy (pirfenidone, nintedanib, or nerandomilast)
- What this could lead to
- If successful, this could help doctors and patients make better-informed decisions about continuing or stopping antifibrotic treatment after side effects.
- What could go wrong
- This is a small, qualitative interview study in Japan only, so findings may not apply to other populations or settings. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Mebix, Inc.
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- AI outruns radiologists in detecting early lung scarring
- Experimental drug aims to slow lung scarring in IPF
- AI-Designed drug targets scarred lungs in major trial
- Tracking lung scarring: new registry aims to map progressive pulmonary fibrosis in china